polycystic liver disease
Conditions
Brief summary
The primary outcome variable is liver growth rate (in % per year), calculated over the first 18 months of the trial (screening-18 months) based on liver volumes measured on MRI, comparing the direct start group and delayed start group.
Detailed description
Polycystic liver disease related complaints, using the validated PLD Questionnaire. The change in the score on the PLD Questionnaire will be compared between patients in the direct start group and the delayed start group after 18 months of treatment., Liver growth rate (in % per year) compared within individuals before start of treatment and during treatment., (Severe) Adverse events
Interventions
DRUGLEUPRORELIN
Sponsors
Universitair Medisch Centrum Groningen
Eligibility
Sex/Gender
All
Age
18 Years to 64 Years
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The primary outcome variable is liver growth rate (in % per year), calculated over the first 18 months of the trial (screening-18 months) based on liver volumes measured on MRI, comparing the direct start group and delayed start group. | — |
Secondary
| Measure | Time frame |
|---|---|
| Polycystic liver disease related complaints, using the validated PLD Questionnaire. The change in the score on the PLD Questionnaire will be compared between patients in the direct start group and the delayed start group after 18 months of treatment., Liver growth rate (in % per year) compared within individuals before start of treatment and during treatment., (Severe) Adverse events | — |
Countries
Netherlands
Outcome results
None listed